46 results
424B5
SCNI
Scinai Immunotherapeutics Ltd
19 Sep 23
Prospectus supplement for primary offering
10:03am
commitment by the Placement Agent to purchase any of our securities and the Placement Agent is not required to arrange the purchase or sale of any … offered by this prospectus may be sold:
through agents;
to or through one or more underwriters on a firm commitment or agency basis;
through put or call
424B2
SCNI
Scinai Immunotherapeutics Ltd
28 Aug 23
Prospectus for primary offering
4:01pm
underwriters on a firm commitment or agency basis;
through put or call option transactions relating to the securities;
in “at the market offerings
F-3
SCNI
Scinai Immunotherapeutics Ltd
18 Aug 23
Shelf registration (foreign)
4:16pm
be sold:
through agents;
to or through one or more underwriters on a firm commitment or agency basis;
through put or call option transactions
10-Q
2023 Q1
SCNI
Scinai Immunotherapeutics Ltd
15 May 23
Quarterly report
4:49pm
; however, we have not secured any commitment for new financing at this time nor can we provide any assurance that new financing will be available
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials … or private equity offerings, debt financings, corporate collaborations or other means; however, we have not secured any commitment for new financing
6-K
EX-1.1
y7gwb
20 Dec 22
BiondVax Announces Closing of $8 Million Underwritten Public Offering
5:29pm
424B4
57hb2oyxzu458k
20 Dec 22
Prospectus supplement with pricing info
11:59am
F-1/A
EX-1.1
motwt30ixs0cua5p4ag2
14 Dec 22
Registration statement (foreign) (amended)
4:45pm
F-1/A
lxz37j
12 Dec 22
Registration statement (foreign) (amended)
5:25pm
6-K
EX-99.1
t7uqz88 tzt43el4cav7
3 Oct 22
BiondVax announces financial plans to support its ongoing NanoAb pipeline development
4:05pm
F-1
zp7lx bbryz
29 Sep 22
Registration statement (foreign)
9:22am
6-K/A
EX-99.2
ijma71or
29 Aug 22
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
4:51pm
424B5
g0l911abavith gfcy
28 Dec 21
Prospectus supplement for primary offering
5:20pm
424B5
lpeg08bzxsv
27 Dec 21
Prospectus supplement for primary offering
6:22am
424B5
hh8gzwc 76
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
b3x84belnjyclx7hi4me
29 Jan 21
Prospectus supplement for primary offering
12:00am
6-K
EX-1.1
e7ohfm
2 Oct 20
BiondVax Announces At-The-Market (ATM) Equity Offering Program
12:00am